Talis Biomedical Corp. (TLIS) PT Lowered to $16 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TLIS Hot Sheet
Price: $4.38 --0%
Rating Summary:
0 Buy, 1 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
0 Buy, 1 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
BTIG analyst Mark Massaro lowered the price target on Talis Biomedical Corp. (NASDAQ: TLIS) to $16.00 (from $18.00) while maintaining a Buy rating.
You May Also Be Interested In
- AMD (AMD) PT Raised to $600 at DA Davidson
- Red Rock Resorts (RRR) PT Lowered to $60 at StoneX
- Freshworks Inc (FRSH) PT Raised to $17 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
